STUDY OF ADHERENCE RATES AND SIDE EFFECTS OF ORAL TREATMENTS IN POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTEMIA (OUEST STUDY)
(Abstract release date: 05/19/16)
EHA Library. LE CALLOCH R. 06/09/16; 132911; E1362
Dr. Ronan LE CALLOCH
Contributions
Contributions
Abstract
Abstract: E1362
Type: Eposter Presentation
Background
Polycythemia vera (PV) and essential thrombocythemia (ET) are two chronic hematological malignancies with no curative project. International consensus recommends combining long-term low dose antiplatelet drug and a cytoreductive therapy to reduce hyperviscosity (thrombosis) and phenotypic evolutions (myelofibrosis and acute leukemia). There is actually no study in the literature which evaluates the level of adherence in this population.
Aims
The aim of our study was to evaluate patient adherence rate to physicians prescriptions, explore the reasons and identify the occurrence of side effects.
Methods
A total of 134 patients treated for PV or ET with a median follow-up of 6.8 years were asked for about their adherence using a one-shot questionnaire designed by investigators. Data on complications (thrombosis and industrial) were collected from diagnosis to the time of consultation. All the patients signed inform consent before completing the form.
Results
Twenty-eight percent (37 patients) of the patients reported non-adherence to their cytoreductive drug. Patients who forgot their anti-platelet or anti-coagulant drugs (22 patients=X%) are mostly those who belong to the first non-adherent group (15/22; p <0.0001). In total, 44 patients (32.8%) were declared as non-adherent. A typical profile of these patients could be described: patient who lives alone (p = 0.007), rather young (p = 0.06) and male (p = 0.09). The main cause of non-compliance was oblivion (23/37, 69.7%). Polymedicated patients were significantly more adherent (p = 0.001). Thrombotic history were recorded in 21.7% of patients (21/97) members against 24.3% of non-adherent patients (9/37) (p = 0.74). On the other hand, myelofibrotic evolutions were more seen in adherent group (14.4% vs 5.4%, p = 0.233). Side effects related to anti-proliferative treatments were reported by 101 patients (75.4%), and were most frequently cutaneous (53/101, 52.5%) or mucosal toxicity (16/101, 15.8%) likely due to the high prevalence of hydroxycarbamide (94/134, 70%).
Conclusion
For patients treated for PV or ET, non-adherence to anti-proliferative treatment and anti-agregant therapy seems to be frequent. We did not found any correlation with history of thrombosis and myelofibrotic evolution. The patients will be followed for five years to assume the occurrence of new events instead to correlate them with adherence in a prospective way. An analysis of data on a total population of 286 patients will be presented at the conference.
Session topic: E-poster
Keyword(s): Adhesion, Myeloproliferative disorder, Therapy
Type: Eposter Presentation
Background
Polycythemia vera (PV) and essential thrombocythemia (ET) are two chronic hematological malignancies with no curative project. International consensus recommends combining long-term low dose antiplatelet drug and a cytoreductive therapy to reduce hyperviscosity (thrombosis) and phenotypic evolutions (myelofibrosis and acute leukemia). There is actually no study in the literature which evaluates the level of adherence in this population.
Aims
The aim of our study was to evaluate patient adherence rate to physicians prescriptions, explore the reasons and identify the occurrence of side effects.
Methods
A total of 134 patients treated for PV or ET with a median follow-up of 6.8 years were asked for about their adherence using a one-shot questionnaire designed by investigators. Data on complications (thrombosis and industrial) were collected from diagnosis to the time of consultation. All the patients signed inform consent before completing the form.
Results
Twenty-eight percent (37 patients) of the patients reported non-adherence to their cytoreductive drug. Patients who forgot their anti-platelet or anti-coagulant drugs (22 patients=X%) are mostly those who belong to the first non-adherent group (15/22; p <0.0001). In total, 44 patients (32.8%) were declared as non-adherent. A typical profile of these patients could be described: patient who lives alone (p = 0.007), rather young (p = 0.06) and male (p = 0.09). The main cause of non-compliance was oblivion (23/37, 69.7%). Polymedicated patients were significantly more adherent (p = 0.001). Thrombotic history were recorded in 21.7% of patients (21/97) members against 24.3% of non-adherent patients (9/37) (p = 0.74). On the other hand, myelofibrotic evolutions were more seen in adherent group (14.4% vs 5.4%, p = 0.233). Side effects related to anti-proliferative treatments were reported by 101 patients (75.4%), and were most frequently cutaneous (53/101, 52.5%) or mucosal toxicity (16/101, 15.8%) likely due to the high prevalence of hydroxycarbamide (94/134, 70%).
Conclusion
For patients treated for PV or ET, non-adherence to anti-proliferative treatment and anti-agregant therapy seems to be frequent. We did not found any correlation with history of thrombosis and myelofibrotic evolution. The patients will be followed for five years to assume the occurrence of new events instead to correlate them with adherence in a prospective way. An analysis of data on a total population of 286 patients will be presented at the conference.
Session topic: E-poster
Keyword(s): Adhesion, Myeloproliferative disorder, Therapy
Abstract: E1362
Type: Eposter Presentation
Background
Polycythemia vera (PV) and essential thrombocythemia (ET) are two chronic hematological malignancies with no curative project. International consensus recommends combining long-term low dose antiplatelet drug and a cytoreductive therapy to reduce hyperviscosity (thrombosis) and phenotypic evolutions (myelofibrosis and acute leukemia). There is actually no study in the literature which evaluates the level of adherence in this population.
Aims
The aim of our study was to evaluate patient adherence rate to physicians prescriptions, explore the reasons and identify the occurrence of side effects.
Methods
A total of 134 patients treated for PV or ET with a median follow-up of 6.8 years were asked for about their adherence using a one-shot questionnaire designed by investigators. Data on complications (thrombosis and industrial) were collected from diagnosis to the time of consultation. All the patients signed inform consent before completing the form.
Results
Twenty-eight percent (37 patients) of the patients reported non-adherence to their cytoreductive drug. Patients who forgot their anti-platelet or anti-coagulant drugs (22 patients=X%) are mostly those who belong to the first non-adherent group (15/22; p <0.0001). In total, 44 patients (32.8%) were declared as non-adherent. A typical profile of these patients could be described: patient who lives alone (p = 0.007), rather young (p = 0.06) and male (p = 0.09). The main cause of non-compliance was oblivion (23/37, 69.7%). Polymedicated patients were significantly more adherent (p = 0.001). Thrombotic history were recorded in 21.7% of patients (21/97) members against 24.3% of non-adherent patients (9/37) (p = 0.74). On the other hand, myelofibrotic evolutions were more seen in adherent group (14.4% vs 5.4%, p = 0.233). Side effects related to anti-proliferative treatments were reported by 101 patients (75.4%), and were most frequently cutaneous (53/101, 52.5%) or mucosal toxicity (16/101, 15.8%) likely due to the high prevalence of hydroxycarbamide (94/134, 70%).
Conclusion
For patients treated for PV or ET, non-adherence to anti-proliferative treatment and anti-agregant therapy seems to be frequent. We did not found any correlation with history of thrombosis and myelofibrotic evolution. The patients will be followed for five years to assume the occurrence of new events instead to correlate them with adherence in a prospective way. An analysis of data on a total population of 286 patients will be presented at the conference.
Session topic: E-poster
Keyword(s): Adhesion, Myeloproliferative disorder, Therapy
Type: Eposter Presentation
Background
Polycythemia vera (PV) and essential thrombocythemia (ET) are two chronic hematological malignancies with no curative project. International consensus recommends combining long-term low dose antiplatelet drug and a cytoreductive therapy to reduce hyperviscosity (thrombosis) and phenotypic evolutions (myelofibrosis and acute leukemia). There is actually no study in the literature which evaluates the level of adherence in this population.
Aims
The aim of our study was to evaluate patient adherence rate to physicians prescriptions, explore the reasons and identify the occurrence of side effects.
Methods
A total of 134 patients treated for PV or ET with a median follow-up of 6.8 years were asked for about their adherence using a one-shot questionnaire designed by investigators. Data on complications (thrombosis and industrial) were collected from diagnosis to the time of consultation. All the patients signed inform consent before completing the form.
Results
Twenty-eight percent (37 patients) of the patients reported non-adherence to their cytoreductive drug. Patients who forgot their anti-platelet or anti-coagulant drugs (22 patients=X%) are mostly those who belong to the first non-adherent group (15/22; p <0.0001). In total, 44 patients (32.8%) were declared as non-adherent. A typical profile of these patients could be described: patient who lives alone (p = 0.007), rather young (p = 0.06) and male (p = 0.09). The main cause of non-compliance was oblivion (23/37, 69.7%). Polymedicated patients were significantly more adherent (p = 0.001). Thrombotic history were recorded in 21.7% of patients (21/97) members against 24.3% of non-adherent patients (9/37) (p = 0.74). On the other hand, myelofibrotic evolutions were more seen in adherent group (14.4% vs 5.4%, p = 0.233). Side effects related to anti-proliferative treatments were reported by 101 patients (75.4%), and were most frequently cutaneous (53/101, 52.5%) or mucosal toxicity (16/101, 15.8%) likely due to the high prevalence of hydroxycarbamide (94/134, 70%).
Conclusion
For patients treated for PV or ET, non-adherence to anti-proliferative treatment and anti-agregant therapy seems to be frequent. We did not found any correlation with history of thrombosis and myelofibrotic evolution. The patients will be followed for five years to assume the occurrence of new events instead to correlate them with adherence in a prospective way. An analysis of data on a total population of 286 patients will be presented at the conference.
Session topic: E-poster
Keyword(s): Adhesion, Myeloproliferative disorder, Therapy
{{ help_message }}
{{filter}}